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Abstract 32 
 33 
Background 34 
Cancer impacts on patients and their families across a range of different domains. For that 35 
reason, optimal cancer care has moved away from a disease-centric focus to a more holistic 36 
approach in order to proactively support people with their individual needs and concerns. 37 
While international policy clearly advocates this agenda, implementation into routine care is 38 
limited. Therefore, relevant interventions that measurably improve patient outcomes are 39 
essential to understand if this ideal is to become routine multidisciplinary practice. The aim 40 
of this study was to analyse the impact of a proactive, holistic, community-based 41 
intervention on health-related quality of life in a cohort of people diagnosed with cancer. 42 
Secondary aim was to explore the relationship between changes in health status and: cancer 43 
type, cancer stage, number of concerns expressed and change in severity of concerns pre 44 
and post intervention. 45 
Method 46 
Prospective observational cohort study. A convenience sample of 437 individuals were 47 
referred to the service ‘Improving the Cancer Journey (ICJ) in the UK. Each completed the 48 
Euroqol EQ-5D-3L and visual analogue scale (VAS) and a Holistic Needs Assessment (HNA) 49 
during initial visit to the service and again at follow-up review, median 84 days later. Change 50 
between scores was tested with paired t-tests and relationships between variables with 51 
multiple regression models with heteroscedasticity-consistent standard errors.  52 
Results 53 
Participants were White British with median age between 50-64 years. Cancer type and 54 
stage were varied. EQ-5D utility scores improved at follow-up by 0.121 [0.0891-0.153], 55 
p<.001, and VAS scores improved by 7.81 [5.88-9.74], p<.001. The strongest predictor of 56 
change was a decrease in severity of concerns. Cancer stage ‘palliative care’ contributed to a 57 
reduction in health status.  58 
Conclusion 59 
This study is the first to show that a holistic community intervention dedicated to supporting 60 
the individual concerns of participants had both a statistically significant and clinically 61 
meaningful impact on participants’ health-related quality of life. The mean change in EQ-5D 62 
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scores was more than the ‘minimally important clinical difference’ described in the 63 
literature. This is important because while quality of life has multiple determinants, this 64 
study has shown for the first time that it is possible to capture a clinically meaningful 65 
improvement as a function of reducing someone’s personally identified concerns. 66 
  67 
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 72 
Background 73 
Globally, following a cancer diagnosis people report a wide range of needs and concerns [1]. 74 
The ideal of modern health and social care is therefore to optimise the skills available from a 75 
matching range of multidisciplinary professionals to meet these physical, psychological, 76 
social, emotional, financial, practical and spiritual needs, whilst at all times keeping the 77 
individual at the centre of decisions [2].  78 
 79 
However, evidencing the benefits of holistic approaches to the patient is complex, not least 80 
because there are numerous interacting factors that impact on outcomes. For instance, 81 
there are different approaches to providing holistic care, including different assessment 82 
tools and assessor actions that affect the patient experience [3][4]. Even using the same 83 
assessment, individuals respond in different ways according to the professional undertaking 84 
the assessment [5], suggesting that there is no such thing as a ‘value free’ assessment of 85 
holistic need. Consequently, while policy has recognised the importance of routine, person-86 
centred, psychosocial care [6], concerns relating to implementation barriers, the lack of 87 
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clarity on the best way to identify needs and poor evidence of impact prevents widespread 88 
uptake [7][8]. Nevertheless, successful interventions exist. Therefore, the most appropriate 89 
learning at present comes from successful examples of care delivery consistent with this 90 
holistic agenda.  91 
 92 
The intervention – Improving the Cancer Journey 93 
‘Improving the Cancer Journey’ (ICJ) was commissioned in 2014 in Glasgow, Scotland. It is 94 
the first community-based cancer service of its kind in the UK and is unique for three 95 
interrelated reasons. First, stakeholders are multi-professional. Led by the city council with 96 
partners across health, social care, housing and the third sector. Second, the key 97 
intervention (Holistic Needs Assessment (HNA) figure 1) is proactive: people newly 98 
diagnosed with cancer are actively sought out and referred to support. Third, the 99 
intervention is coordinated by non-clinical ‘link officers’ rather than health professionals 100 
(table 1).  101 
 102 
The link officer 
ICJ link officers are city council employees, not health care professionals. The council 
currently employ seven link officers. When they first join the service, link-officers have a 3-
month induction period where each officer becomes familiar with their role and 
completes a range of training. Currently all officers are, or are working towards, being 
accredited with a Level 3 Scottish Vocational Qualification (SVQ) in healthcare support to 
reflect their competencies in this area. Level 3 SVQ is a vocational qualification 
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academically equivalent to graduate diploma level, or second year of baccalaureate 
degree.  
 103 
Table 1 The link officer 104 
 105 
In more detail, ICJ writes to every person with a confirmed cancer diagnosis in Glasgow and 106 
invites them to access the support, if they wish. At a pre-arranged appointment the link 107 
officer meets with their client at a location of their choice. This may be their home, a 108 
community venue such as a library or their local hospital (both inpatient and outpatient). 109 
During this appointment a HNA (figure 1) is carried out, whereby clients are asked to score 110 
each of their identified concerns from zero to 10, reflecting the severity of the concern for 111 
that person. Based on mutually agreed priorities between the patient and link officer, a care-112 
plan is then co-constructed which details any actions that will be carried out to support the 113 
identified concerns. For example, the link officer may provide written information or make a 114 
referral to an appropriate agency. The link officer revisits each case; the timing dependant 115 
on the clients’ circumstances, severity of concerns raised, care plan details and prognosis. At 116 
this review, a second HNA is carried out to identify if the client’s concerns have reduced 117 
and/or there are any new concerns. This process continues until the client and the link 118 
officer are satisfied that no further support is required.  119 
 120 
The service has supported approximately 4000 people since 2014 across a range of cancer 121 
types and stages and sociodemographic backgrounds [9]. However, the most common use of 122 
the service is from individuals with lung cancer, who are aged between 55-64 years and who 123 
live in areas of high deprivation, as measured by the Scottish Index of Multiple Deprivation 124 
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(SIMD). Thirty per cent of ICJ clients were receiving treatment at the time of their first HNA. 125 
Most (over 50%) have at least one co-morbidity. The top three concerns for all users of ICJ 126 
are financial, fatigue and worry/anxiety. Actions taken by the service include referral to 127 
organisations for financial support (including payment of state benefits), referral to other 128 
charities for services such as counselling and complementary therapies and referral to social 129 
care for assistance with daily living.  130 
 131 
There is quantitative and qualitative evidence that this service generates positive outcomes 132 
for individuals [9, 10]. Demonstrating a national commitment to this model of care in 2019, 133 
Macmillan Cancer Support (a UK charity) and the Scottish Government each pledged £9 134 
million to ensure everyone diagnosed with cancer has a dedicated support worker. 135 
According to the Scottish Government [11] this will make Scotland the first country in the UK 136 
to offer cancer patients guaranteed emotional, practical and financial advice . 137 
 138 
However, despite this public support it remains unclear what, if any, relationship there is 139 
between identifying and meeting someone’s personally identified needs and any subsequent 140 
impact on self-reported health status. This is important as it would provide currently lacking 141 
evidence of effectiveness using standardised measures. In turn, this will improve the ability 142 
to generalise findings to other geographical and cancer care settings and lay the foundation 143 
for future research to develop a conceptual theory on the relationship between ‘need’ 144 
(which may cover a number of domains) and health related quality of life [12].  145 
 146 
 147 
 148 
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Aim 149 
The overarching aim was to analyse the impact of ICJ on self-reported health status using the 150 
EQ-5D - 3L utility measure and visual analogue scale (VAS) [13]. Secondary aim was to 151 
explore the relationships between change in health status and cancer type, cancer stage, 152 
number of HNA concerns expressed, severity of concerns and change in severity of concerns 153 
between pre and post intervention. 154 
 155 
Hypotheses 156 
Primary:  157 
1. There will be a statistically significant difference between EQ-5D scores at baseline 158 
and EQ-5D scores post intervention. 159 
Secondary:  160 
2. There will be a relationship between changes in health status and: cancer type, 161 
cancer stage, number of concerns expressed and change in severity of concerns pre 162 
and post intervention. 163 
 164 
Method 165 
Design 166 
Prospective observational cohort study.  167 
 168 
Analytic variables  169 
Sociodemographic data included age range, sex, and Scottish Index of Multiple Deprivation 170 
(SIMD). These data were collected with consent from the participants who had accessed the 171 
intervention at baseline. The following data were collected at baseline and also post 172 
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intervention: cancer type, cancer stage, and data relating to the HNA process (figure 1) 173 
including number and mean severity rating of concerns identified. To measure self-reported 174 
health status, participants completed the EQ-5D-3L and Visual Analogue Scale (VAS) at 175 
baseline and post intervention. A utility score was computed from the EQ-5D ratings using 176 
an algorithm and value sets produced in a UK population study [14] of societal preferences 177 
using the Time Trade-off (TTO) method. A utility score of 1 is interpreted as the best possible 178 
health, 0 as death, and values of <0 as being worse than death. 179 
 180 
Participants 181 
In 2018/19 a consecutive, convenience sample of 437 ICJ clients completed the EQ-5D-3L 182 
and VAS on paper versions during their initial visit and again at their follow-up review. Initial 183 
assessments were face to face so individuals completed the surveys themselves. Reviews 184 
usually occurred over the telephone so the link officer, through conversation, completed it 185 
on the participants’ behalf.  186 
 187 
Analytic plan 188 
All data were imported into R (version 3.5.0, using ‘tidyverse’ package version 1.3.0 [15]) and 189 
SPSS package for statistics version 23, cleaned and checked for outliers. For the main 190 
hypothesis, a paired t-test was run to ascertain the difference in EQ-5D-3L scores between 191 
initial visit and post intervention, and the same for the VAS. For the secondary aim, EQ-5D-3L 192 
and VAS change scores post intervention were tested for associations using univariate linear 193 
regressions with sociodemographic, clinical and HNA-related variables, with those found 194 
associated entered into two multiple linear regression models to identify likely predictors of 195 
change in EQ-5D scores and VAS between assessments. For descriptive statistics, means and 196 
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confidence intervals were computed for approximately normally distributed variables, 197 
proportions for categorical variables, and median and minima and maxima for non-normally 198 
distributed variables. Only pairwise complete observations were used in analysis. 199 
 200 
Regarding interpretation, the concept of ‘minimally important clinical difference’ (MICD) has 201 
been used to explain the amount of change required in a particular test score that 202 
represents a clinically meaningful change for the individual taking that test.  For example, it 203 
has been used to interpret change in measures of asthma control [16] and wellbeing [17], 204 
including the EQ5D [18], and so this concept was also applied here. 205 
 206 
 207 
Figure 2. Sample inclusions and exclusions. 208 
 209 
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Results 210 
HNA data and EQ-5D results at baseline and follow-up were obtained for 349 individuals as 211 
not every client opts to have a HNA or has a Review (as of August 2019, approximately 6800 212 
clients were referred to ICJ, with approx. 4100 or 60% of referrals completing a HNA, and 213 
approx. 1800 or 43% of HNAs also receiving a follow-up HNA). As detailed in Figure 2, twelve 214 
participants were excluded for not having had any concerns recorded at HNA or review, four 215 
participants were removed for having baseline and follow-up scores recorded less than 14 216 
days apart, one participant was removed for reporting an unusually large number of 217 
concerns in their HNA, and one participant was removed for having an incomplete EQ5D. A 218 
total of 331 individuals were analysed. The time between assessments ranged from 14 to 219 
456 days, averaging 117 days (median 84). Between baseline and follow up, self reported 220 
severity of concern dropped, in line with previous findings [9]. Figure 3 shows the mean 221 
change in the different domains of the HNA. There is further detail in supplementary file 1.  222 
 223 
 224 
 225 
Figure 3 Baseline, Follow-up and Change score for Mean concern severity across domains. 226 
Error bars depict 95% CI. The negative change scores correspond to an improvement. 227 
 228 
 229 
 230 
 231 
 232 
 233 
 234 
 235 
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 236 
Table 2 shows patient characteristics. In summary, the majority of participants were aged 237 
between 50-64 years, 59% were female, most resided in areas of high deprivation and 238 
cancer type and stage were varied. The variable ‘Palliative care’ denotes individuals who 239 
identified as receiving palliative care at baseline or follow-up.  240 
 241 
Characteristic Statistic  N  
Age, N (%):  330 
    25 to 49 years 32 (9.70%)     
    50 to 64 years 127 (38.5%)     
    65 to 74 years 112 (33.9%)     
    75 years and over 59 (17.9%)     
Sex, N (%):  325 
    Female 192 (59.1%)     
    Male 133 (40.9%)     
Cancer type, N (%):  331 
    Bowel 29 (8.76%)     
    Breast 71 (21.5%)     
    Lung 72 (21.8%)     
    Pther 131 (39.6%)     
    Prostate 28 (8.46%)     
Cancer stage at baseline, N (%):  273 
    Living with condition 55 (20.1%)     
    Receiving palliative care 26 (9.52%)     
    Recently completed treatment (within 1 month) 17 (6.23%)     
    Recently diagnosed (1 month) 35 (12.8%)     
    Undergoing tests 18 (6.59%)     
    Undergoing treatment 122 (44.7%)     
Cancer stage at follow-up, N (%):  322 
    Living with condition 144 (44.7%)     
    Receiving palliative care 55 (17.1%)     
    Recently completed treatment (within 1 month) 28 (8.70%)     
    Recently diagnosed (1 month) 1 (0.31%)     
    Recurrence 1 (0.31%)     
    Undergoing tests 9 (2.80%)     
    Undergoing treatment 84 (26.1%)     
Palliative care, N (%):  276 
    Yes 59 (21.4%)     
    No 217 (78.6%)     
Deprivation (1=most deprived), Median [min-max] 3 [1-20] 331 
Table 2. Patient characteristics  242 
 243 
12 
 
 244 
Primary Hypothesis  245 
1. There will be a statistically significant difference between EQ-5D scores at baseline 246 
and EQ-5D scores post intervention. 247 
Table 3 presents the descriptives of the EQ-5D-3L Utility score and Visual Analogues Scale 248 
(VAS) at baseline and follow-up. Figure 4 shows the same data but for each individual 249 
participant in spaghetti plots. Both EQ-5D measures increased, indicating an improvement in 250 
health status. The distributions of change scores for EQ-5D utility scores and VAS were 251 
approximately normal with heavier tails on the positive side, and a large proportion of 0 252 
values. However, because the sample size was sufficiently large, the t-test was assumed to 253 
be sufficiently robust to non-normality (Lund & Lund, 2019).  254 
Outcome Mean [95% CI] 
Follow-up time (days)    117 [107;126]    
Concern severity at baseline  6.47 [6.23;6.71]   
Concern severity at follow-up  2.90 [2.66;3.13]   
Concern severity difference at follow-up -3.57 [-3.84;-3.30] 
VAS at baseline  49.1 [47.1;51.1]   
VAS at follow-up  56.9 [54.9;58.9]   
VAS difference at follow-up  7.81 [5.88;9.74]   
Utility score at baseline  0.45 [0.42;0.49]   
Utility score at follow-up  0.58 [0.55;0.60]   
Utility score difference at follow-up  0.12 [0.09;0.15]   
Table 3. Descriptive summary of outcomes. The negative difference in concern severity is 255 
interpreted as an improvement. 256 
 257 
Using a paired t-test, the increase in EQ-5D utility scores of 0.121 [0.0891-0.153] at follow-up 258 
was found to be statistically significant (p<.001), as was the increase in VAS of 7.81 [5.88-259 
9.74] (p<.001). Cohen’s d effect sizes were 0.43 [0.27-0.58] for Utility score difference, and 260 
0.42 [0.27-0.58] for VAS, both of which are considered small to moderate. The hypothesis of 261 
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a significant difference between baseline and follow-up on EQ-5D scores was supported. The 262 
mean changes in EQ-5D scores fell within previously published Minimal Clinically Important 263 
Difference (MCID) estimates for oncological patients: 0.07 to 0.12 for utility scores[20], and 7 264 
to 12 for VAS [21]. Table 3 shows the estimated proportion of individuals who had a clinically 265 
important improvement or decline using the reported MCID values as lower and upper 266 
bounds. 267 
Measure Declined Improved 
Utility score 12.7 - 17.5% 41.7 - 48.6% 
VAS 6.3 - 13.6% 30.5 - 48.0% 
Table 3. Proportion of individuals whose EQ5D scores improved or declined above the MCID 268 
threshold, using published lower and upper bound estimates.  269 
 270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
Figure 4. Spaghetti plots showing change of EQ5D Utility scores and VAS from baseline to 280 
follow-up for each participant. Each partly transparent line segment denotes one participant, 281 
with darker lines indicating overlapping trajectories. The follow-up score is marked with a 282 
circle for clarity.  283 
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Secondary hypothesis 284 
2. There will be a relationship between changes in self-reported health related quality 285 
of life and: cancer type, cancer stage, number of concerns expressed, and change in 286 
severity of concerns pre and post intervention. 287 
 288 
Univariate regressions of EQ-5D scores on age group, gender, cancer type, cancer stage, 289 
palliative care, deprivation level, number of concerns reported, follow-up time, and mean 290 
change in concerns between assessments can be found in Table 4. Variables that were 291 
statistically significantly (p < .05) associated with EQ-5D scores were entered into multiple 292 
regression models (Table 5). The variables used were: time elapsed between EQ-5D 293 
assessments, mean change in concerns between assessments, and palliative care, with the 294 
EQ-5D utility score model also using number of concerns as predictor. Utility score 295 
differences were only significantly different between 25-49 years, and 75 years and over, so 296 
Age was not included in the multiple regression. 297 
 298 
   Utility score   VAS 
Variable N   Beta 95% CI 
p-
value   Beta 95% CI 
p-
value 
Age 330                 
25 to 49 years     — —     — —   
50 to 64 years     -0.11 
-0.22, 
0.01 0.068   -4.7 -12, 2.2 0.2 
65 to 74 years     -0.11 
-0.22, 
0.01 0.067   -5.9 -13, 1.1 0.1 
75 years and over     -0.15 
-0.28, -
0.03 0.019   -5.7 -13, 2.0 0.15 
Sex 325                 
Female     — —     — —   
Male     0.01 -0.05, 0.08 0.7   0.33 -3.6, 4.2 0.9 
Cancer type 331                 
Bowel     — —     — —   
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Breast     0 -0.13, 0.12 >0.9   
-
0.99 -8.7, 6.8 0.8 
Lung     -0.02 
-0.15, 
0.11 0.7   -3.5 -11, 4.2 0.4 
Other     0.03 -0.08, 0.15 0.6   0.07 -7.1, 7.3 >0.9 
Prostate     0.08 -0.07, 0.23 0.3   1.6 -7.7, 11 0.7 
Cancer stage at baseline 273                 
Living with condition     — —     — —   
Receiving palliative care     -0.08 
-0.21, 
0.06 0.3   -3.3 -11, 4.9 0.4 
Recently completed treatment (within 
1 month)     0.04 
-0.12, 
0.19 0.7   1.3 -8.2, 11 0.8 
Recently diagnosed (1 month)     0.08 -0.04, 0.20 0.2   
-
0.32 -7.7, 7.0 >0.9 
Undergoing tests     0.21 0.05, 0.36 0.008   0.76 -8.5, 10 0.9 
Undergoing treatment     0.06 -0.04, 0.15 0.2   3 -2.6, 8.5 0.3 
Cancer stage at follow-up 322                 
Living with condition     — —     — —   
Receiving palliative care     -0.08 
-0.18, 
0.01 0.075   -9 -15, -3.5 0.001 
Recently completed treatment (within 
1 month)     
-
0.03 
-0.15, 
0.09 0.6   2.2 -4.9, 9.4 0.5 
Recently diagnosed (1 month)     -0.13 
-0.72, 
0.45 0.6   -9.9 -45, 25 0.6 
Recurrence     0.45 -0.13, 1.0 0.13   -4.9 -40, 30 0.8 
Undergoing tests     0.05 -0.15, 0.25 0.6   -11 -23, 1.2 0.077 
Undergoing treatment     -0.01 
-0.09, 
0.07 0.8   -2.8 -7.5, 2.0 0.3 
Palliative care 276                 
Yes     — —     — —   
No     0.09 0.01, 0.18 0.029   6.6 1.7, 12 0.008 
Deprivation (1=most deprived) 331   0 -0.01, 0.00 0.2   0.06 
-0.34, 
0.45 0.8 
Number of concerns at baseline 331   0.02 0.00, 0.03 0.025   0.46 -0.37, 1.3 0.3 
Mean change in concern severity at 
follow-up 331   
-
0.03 
-0.04, -
0.02 <0.001   -1.2 
-1.9, -
0.39 0.003 
Follow-up time (30 day increments) 331   0.02 0.01, 0.03 0.003   1.2 0.56, 1.9 <0.001 
Table 4. Univariate regressions of patient characteristics and outcomes on EQ-5D scores; p-299 
values significant at α<.05 shown in bold. Follow-up time in multiples of 30 day increments 300 
was defined as the number of days divided by 30 to approximate number of months. 301 
 302 
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Both the EQ-5D utility score and VAS models were heteroscedastic so White’s 303 
heteroscedasticity-consistent standard errors were used (HC0, using R ‘sandwich’ package 304 
version 2.5-1) [22][23]. Following assumption testing [19], the omnibus test of the EQ-5D 305 
utility score model was significant at F(4,271) = 13.9, p < .001, adj. R2 = .158, with regression 306 
terms Mean change in concern severity between assessments significant at p < .001, 307 
Palliative care significant at p < .01, and Number of concerns significant at p < .05. Time 308 
elapsed between assessments was not a significant predictor. The omnibus test of the VAS 309 
score model was significant at F(3,272) = 8.6, p < .001, adj. R2 = .076, with regression terms 310 
Time elapsed between assessments, Mean change in concern severity between assessments 311 
significant at p<.001, and Palliative care statistically significant at p < .0001. Regression 312 
coefficients, robust standard errors and confidence intervals for both models can be found in 313 
Table 5. 314 
 315 
HNA average score decreased, indicating a reduction in severity of concerns (figure 3). The 316 
mean concern severity was 6.47 [6.23-6.71] at baseline, dropping to 2.90 [2.66-3.13] post 317 
intervention. Only three individuals (<1%) showed increase in severity of concern post 318 
intervention. Mean concern severity was independent of the number of concerns 319 
(Spearman’s ρ=.076, p=.17). In the EQ-5D utility score change model, the strongest predictor 320 
was Mean concern change (β=-0.34), meaning that a one standard deviation (1SD) decrease 321 
in concern severity at follow-up corresponded to a 0.34SD increase in utility score. Next 322 
strongest predictor was Palliative care, which contributed -0.408SD to the EQ-5D utility 323 
score change. Finally, when the number of concerns increased by 1SD, the utility score 324 
increased by 0.13SD. The time elapsed between EQ-5D assessments was not a significant 325 
predictor in the model. 326 
 327 
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In the VAS model, the strongest predictor was Palliative care, which contributed 328 
approximately -8 points on the VAS scale, followed by Mean concern change, where a 1SD 329 
decrease in concerns corresponded to a 0.17SD increase in VAS. Time elapsed between 330 
assessments was a significant predictor of VAS change in the model, corresponding to a 331 
0.16SD increase in VAS in a 1SD time increase. 332 
 333 
  EQ5D-3L Utility value change EQ5D VAS change 
Predictors Estimates 
std. 
Beta CI 
standardized 
CI p Estimates 
std. 
Beta CI 
standardized 
CI p 
Intercept -0.109 
 
-0.195 – -0.022 
 
0.014 0.459 
 
-3.370 – 4.287 
 
0.814 
Time elapsed (30 day 
increment) 
0.012 0.102 -0.007 – 0.030 -0.011 – 0.216 0.207 1.076 0.157 0.122 – 2.030 0.040 – 0.274 0.027 
Mean concern change -0.04 -0.343 -0.055 – -0.024 -0.456 – -0.230 <0.001 -1.132 -0.166 -2.155 – -0.109 -0.284 – -0.048 0.03 
Number of concerns at 
baseline 
0.016 0.129 0.001 – 0.032 0.014 – 0.244 0.036 
     
Palliative care -0.12 -0.408 -0.206 – -0.033 -0.283 – -0.052 0.007 -8.636 -0.501 -14.178 – -3.095 -0.322 – -0.090 0.002 
Observations 276 276 
R2 / R2 adjusted 0.170 / 0.158 0.087 / 0.077 
 334 
Table 5. Linear multiple regression with White’s heteroscedasticity-consistent standard errors 335 
for Utility score change and VAS change at follow-up; p-values significant at α<.05 shown in 336 
bold337 
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 338 
Discussion 339 
This study has described a significant association between change in HNA score and self-340 
reported health status. Following intervention from ICJ, mean HNA concern severity reduced 341 
from 6.4 [6.23-6.71] to 2.9 [2.66-3.13], consistent with the decrease seen in the wider ICJ 342 
population [9]. Concurrently, EQ-5D score increased from 0.45 [0.422-0.488] to 0.57 [0.547-343 
0.604], while VAS scores increased from 49 [47.1-51.1] to 57 [54.9-58.9]. This EQ-5D utility 344 
score difference of 0.12 [0.0891-0.153] and VAS difference of 7.81 [5.88-9.74] are 345 
considered to be above the ‘minimally important clinical difference’ (MICD) in EQ-5D scores 346 
described by Coretti et al., [20], and Pickard et al [24]. In other words, this level of 347 
improvement has been described as an important and meaningful improvement for patients 348 
[25]. This is also consistent with qualitative evidence [10] on the perceived benefits of using 349 
ICJ.  350 
 351 
To further contextualise the scores in this study, supplementary file 2 presents mean 352 
baseline and post intervention EQ-5D utility scores from participants in this study, according 353 
to cancer type. The same table also contains a reference range of the highest and lowest 354 
mean EQ-5D utility scores for the same cancer types, obtained from international studies 355 
specifically designed to ascertain EQ-5D population norms. These values show that the ICJ 356 
cohort recorded some of the lowest quality of life scores published in the cancer literature. 357 
The intervention is therefore not just clinically meaningful but also successfully reaching the 358 
population that requires it the most.  359 
 360 
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Overall, the models explained a moderate to small amount of variance (approximately 16% 361 
for utility scores, and 8% for VAS). The strongest predictor was ‘mean concern change’. Over 362 
the same period of time that the EQ-5D scores increased, the HNA mean level of concern 363 
severity decreased. Receiving palliative care and the number of concerns were also 364 
significant predictors, along with time between assessments on the VAS scores, but not the 365 
index scores. However, a proportion of the improvement remains unexplained. There is a 366 
missing explanatory variable, consistent with the interpretation that the process of ICJ is also 367 
contributing to the change in health status. For example, identifying a larger number of 368 
concerns at baseline was associated with increased health status at follow up. This also 369 
points to the process of ICJ being a determinant of improvement: identifying more concerns 370 
leads to more engagement with the services on offer, resulting in better outcomes. 371 
However, this remains unknown at present because there is no measure of impact of specific 372 
services. This hypothesis will be explored in future research by recording attendance and 373 
satisfaction ratings of all the services provided and signposted by ICJ. 374 
 375 
Previous research investigating the association between needs assessment and improved 376 
outcomes has predominantly focused on measuring impact through a range of measurable 377 
outcomes such as distress, anxiety, depression and pain using specific tools such as the 378 
Distress Thermometer (DT) [26–28]. Qualitative evidence on the use of HNA has shown that 379 
it can improve communication between patients and clinicians, providing an opportunity to 380 
discuss non-clinical concerns and signpost patients to a variety of different services [29, 30]. 381 
However, assessment alone does not always lead to improved outcomes. Sandsund et al., 382 
[29] did not find a statistically significant difference in quality of life after using the HNA in 383 
124 women diagnosed with gynaecological cancer. Hollingworth et al. [31] found no 384 
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evidence of an effect on distress or quality of life, and concluded that the timing of the 385 
assessment and the profession of the assessor can impact on outcomes.  386 
 387 
The HNA assessor in ICJ was a non-clinical expert. Link officers come to this role with 388 
backgrounds in financial inclusion and city council processes, and then undertake a three-389 
month training programme to become specialists. They are therefore equipped with a range 390 
of skills and knowledge to help navigate people affected by cancer through the complex 391 
systems within health but especially through social care and the third sector. In other studies 392 
only limited training was provided to the assessors [7]. This is likely to impact on the quality 393 
of the HNA interaction and the knowledge and confidence required to make referrals across 394 
different services and sectors. Further, it is rational to suggest that people tailor responses 395 
to what they perceive to be the expertise of the person conducting the consultation [32]. 396 
Accordingly, in this study participants commonly identified non-clinical concerns such as 397 
finances and worry/anxiety. These concerns have been identified as being a substantial 398 
burden with individuals much more likely to rate their physical health, mental health, and 399 
satisfaction with social activities and relationships as poor compared to those with no 400 
financial hardship [33]. For that reason, relieving financial burden is likely to have had a 401 
substantially positive impact on other areas of concern, which may also add to the 402 
interpretation of the findings in this study.  403 
 404 
Identifying and assessing individual concerns [34–36] is unarguably beneficial as it can help, 405 
amongst other things, with resource allocation. However, to our knowledge, this is the first 406 
study to quantify what this means to individuals’ health related quality of life. This is 407 
important because while quality of life has multiple determinants this study has reported 408 
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that it is possible to capture a meaningful improvement in quality of life as a function of 409 
reducing someone’s personally identified concerns.  410 
 411 
 412 
 413 
Strengths and limitations 414 
The current study has several strengths. This is the first examination of health status over 415 
time in a large and heterogeneous sample of cancer patients who have all been supported 416 
through the HNA process. The primary limitation is that the sample was not random, and the 417 
time between EQ-5D assessments was not standardized. Some degree of improvement over 418 
time was anticipated. The way ICJ functions is that assessments are followed by referrals and 419 
then followed by further ICJ contact. Therefore, over this time period it is likely that 420 
individuals may, for example, finish their treatment and report a higher health status. 421 
However, the time elapsed between assessments was only a significant predictor of 422 
improvement in VAS but not utility scores. Nevertheless, as stated, most of the improvement 423 
was unexplained. While a broad array of variables were considered for the model we 424 
acknowledge that other variables may have influenced the findings. For example, 425 
information on comorbidities and more detailed information on participant’s use of other 426 
services and interactions with other professionals would have been beneficial. Future 427 
research should identify a broader array of variables including sociodemographic, 428 
interpersonal (patient and assessor interaction) and clinical to explore the relationship 429 
between needs assessment and health related outcomes.  430 
 431 
 432 
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Conclusion 433 
The primary aim of this research was to document any changes in self-reported health status 434 
following intervention from a cancer service. Health status significantly increased following 435 
intervention from ICJ. This is noteworthy because at a time where the cancer workforce is 436 
stretched and patient numbers are increasing there is an urgent need to rethink how to use 437 
resources efficiently without negatively impacting on patient care. The fact that the 438 
assessors in this study were non-health based could well be a model to follow – primarily 439 
due to their expertise and the types of concerns they tended to elicit and manage. This 440 
sample had complex needs with a large proportion residing in areas of high deprivation, with 441 
a poor cancer prognosis and with baseline levels of health status that were considerably 442 
lower than other cancer populations. That they can be helped in a clinically meaningful way 443 
bodes well for those needing similarly targeted support in the future. These results 444 
encourage wide application of HNA and supportive care planning combined with approaches 445 
like ICJ that tailor support based on need.  446 
 447 
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